3450 results for «02060+2025年11月股价»
3450 results
What to expect at PCR Tokyo Valves?
Latest learnings on the treatment of asymptomatic severe aortic stenosis from the EARLY TAVR
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.
In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage...
First guidelines for the treatment of LM disease issued by SOLACI and SIAC
22 May 2025 – From EuroPCR 2025
During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.
Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...
One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases
20 May 2025 – From EuroPCR 2025
In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.
They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to...
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...
Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).
The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...
Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Nilesh Pareek and Thomas Keeble discuss the clinical value and future potential of NIRS IVUS, a dual-modality imaging system developed by Nipro that combines intravascular ultrasound with near-infrared spectroscopy.
The Makoto™ system and Dualpro™ catheter allow real-time identification of lipid-rich plaques by providing both...
Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?
22 May 2025 – From EuroPCR 2025
How can physiology guide treatment decisions beyond ischemia detection? In this round-table recorded at EuroPCR 2025, Thomas Engstrøm, Carlos Collet and Jeroen Sonck examine how pullback pressure gradient (PPG) makes it possible to identify the distribution pattern of coronary artery disease—focal or diffuse—based on a continuous...
1-year SELUTION DeNovo results: drug-eluting balloon strategy vs. systematic drug-eluting stent in de novo coronary disease
29 Oct 2025
Guillaume Bonnet interviews Christian Spaulding about the SELUTION DeNovo Trial he presented at TCT 2025, in San Francisco.
Prof. Christian Spaulding, principal investigator of the study, discusses the trial design, key outcomes, breaks down the nuances behind the sirolimus DCB strategy versus contemporary DES, and shares insights...
Author
Author
Duration of DAPT in ACS: The DUAL-ACS Trial
31 Aug 2025
Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.
The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...
Author
Author
Introducing our recognised EuroPCR Networkers!
PCR: Collaborative, inclusive and global
15 Nov 2025 – From PCR London Valves 2025
At PCR, collaboration and inclusion are at the heart of everything we do.
Together, we create an environment where expertise is shared, talents complement each other, and diversity becomes a strength. It is this collective spirit that drives interventional cardiology forward and inspires innovation every day.
During PCR London...
TRIGISTRY: Advancing real-world understanding of tricuspid valve disease
07 Nov 2025
Edoardo Zancanaro interviews Julien Dreyfus and David Messika-Zeitoun about TRIGISTRY, an international registry that builds on the TRI-SCORE — now part of the 2025 ESC guidelines. The study confirms that early referral and optimal reduction of tricuspid regurgitation are key to improving outcomes. The team now...
Redo TAVI: how to treat different TAVI platforms when they fail?
22 May 2025 – From EuroPCR 2025
In this discussion, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.
Together, they address the main challenges faced in repeat procedures - chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies...
1-year SELUTION DeNovo results: what they mean for daily practice
29 Oct 2025
The SELUTION DeNovo trial, presented by Christian Spaulding at TCT 2025, delivers the first head-to-head comparison between a sirolimus DCB strategy and contemporary DES in PCI.
In this review, Salvatore Brugaletta breaks down the 1-year results and what these findings truly mean for everyday lesion-by-lesion decision-making.
Author
Author
Author
ENCIRCLE 1-year outcomes: Shaping the future of MR treatment with the SAPIEN M3 system
18 Nov 2025 – From PCR London Valves 2025
Fabien Praz talks with Mayra Guerrero and Henryk Dreger about the ENCIRCLE trial on the Sapien M3 transcatheter mitral valve, which shows strong safety, durable MR reduction, and improved symptoms, quality of life, and LV remodelling. High-quality CT and echo are essential for #TMVR, which is...
What are the key considerations when managing combined mitral and tricuspid regurgitation?
17 Feb 2026 – From PCR London Valves 2025
Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and multiple comorbidities. Careful assessment—including echocardiography, hemodynamics, and sometimes CT—is crucial to identify the dominant lesion. Surgery is preferred if feasible, but...
Is iatrogenic atrial septum defect closure a necessary procedure?
17 Nov 2025 – From PCR London Valves 2025
Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure...
Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?
17 Nov 2025 – From PCR London Valves 2025
Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends...
